Congressional Inquiry into Alzheimer’s Drug Faults Its Maker and F.D.A.

Health
By BY PAM BELLUCK from NYT Health https://ift.tt/KXs2trN
via IFTTT Drugs (Pharmaceuticals), Alzheimer's Disease, Clinical Trials, Labeling and Labels (Product), Aduhelm (Drug), Advertising and Marketing, Elderly The report said the F.D.A.’s approval process for Aduhelm was “rife with irregularities” and criticized Biogen for setting an “unjustifiably high price.”

Comments

Popular posts from this blog

U.S. Quietly Drafts Plan to End Program That Saved Millions From AIDS

The Jarring Contradiction at the Heart of Kennedy’s Agenda